AZN, Daiichi's Datroway Wins FDA Nod for Expanded Use in Breast CancerZacks Investment Research • 05/25/26
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor CandidatesBusiness Wire • 05/22/26
AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026Business Wire • 05/22/26
EU regulator recommends positive opinion of AstraZeneca's experimental breast cancer drugReuters • 05/22/26
AZN, Daiichi's Enhertu Gets FDA Nod for Two New Breast Cancer SettingsZacks Investment Research • 05/18/26
BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertensionBusiness Wire • 05/18/26
AstraZeneca wins US approval for first-in-class blood pressure drug and expands cancer treatment EnhertuProactive Investors • 05/18/26
AstraZeneca's Imfinzi with pre-surgery drug boosts survival in bladder cancer trialReuters • 05/14/26
Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZenecaBusiness Wire • 05/13/26
BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026Accesswire • 05/12/26
6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash24/7 Wall Street • 05/06/26
AstraZeneca Prostate Drug Wins FDA Panel Backing As Breast Cancer Candidate FaltersBenzinga • 05/01/26